Issue #22 is live ยท Free during beta
Pharma & Life Sciences AI
Recursion, Exscientia, and Insilico Medicine have each committed hundreds of millions to AI-first drug discovery โ and each has surfaced a different failure mode: target hallucination, Phase II collapse, and the IP ownership question no partnership agreement resolved cleanly. The FDA's AI/ML Action Plan is real and moving. Every memo where pharma and life sciences AI created a real board-level decision is here.
Deployment Memo on this topic
The AI Drug Discovery Audit: What Recursion's Platform Bet Means for Every Pharma R&D Leader Committing Budget to an Algorithm's Hypothesis
Recursion acquired Exscientia in 2024. AI-generated drug candidates are entering Phase II trials. The validation gap between computational hypothesis and human biology remains the central risk.
Recent coverage in our daily digest
Pharma & Life Sciences AIhasn't hit the digest yet
We monitor 200+ sources every weekday. The moment something material moves on this topic, it lands in our daily digest โ and on this page.
Get Pharma & Life Sciences AI coverage in your inbox
Every weekday at 8 AM CDT โ one sharp digest covering Pharma & Life Sciences AI and every other AI move that matters. Free during beta.
โ Free during beta ย ยทย โ No credit card ย ยทย โ Unsubscribe anytime